STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer

STAT PlusPharma Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer Drugmakers are placing increasingly big bets on owning their AI infrastructure Manage alerts for this article Email this article Share this article By Brittany TrangJuly 20, 2026 Health Tech Reporter Brittany Trang[email protected]Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01. It’s officially a trend. For the third time in nine months, a pharma company has announced that it is assembling the largest AI supercomputer in the life sciences industry. This time, it is Bristol Myers Squibb. When the company began its partnership with NVIDIA three years ago with a smaller computing cluster, it was focusing on simpler problems with individual AI tools, like protein structure prediction. But “we actually consumed all the space we had,” said Greg Meyers, chief digital & technology officer at BMS.Advertisement Adding extra computing power is necessary for the company now that it’s “become more convinced” that computationally hungry foundation models can give the company valuable insight into how its drug candidates interact with both the body and with disease, Meyers said in an interview with STAT. He mentioned oncology and neurodegeneration as examples of areas where BMS has developed such models. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Artificial intelligence, Bristol Myers Squibb, drug development, Eli Lilly, Roche, STAT+ Submit a correction requestReprints Brittany Trang Health Tech Reporter Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01. STAT+ Newsletter A hitchhiker's guide to the health care AI galaxy Recommended First Opinion July 20, 2026 It’s time to treat pandemics as threats to national security Pharmalot July 20, 2026 STAT Plus: State audit of Medicaid records points to methods used by PBMs to obscure drug costs Advertisement A STAT Investigation July 20, 2026 STAT Plus: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say First Opinion July 20, 2026 My husband’s suicide shows there’s something very wrong with the U.S. insurance industry First Opinion July 18, 2026 Beware the unintended consequences of testosterone screening for military servicemembers Subscriber Picks